Institutes,Name,Phase,Vaccine,Platform,N,Age (years),N doses,Rand.,Design,Location,Start date,Primary completion date,Trial number,Link,Status,Prime boost,Pregnancy,Children
Center for Genetic Engineering/and Biotechnology (peptide #1),CIGB-66,Phase III,CIGB CIGB-66,Protein subunit,48000,19–80,3,Yes,Double-blind,Cuba,22/03/2021,31/07/2021,IG/CIGB-66I/CVD19/2103,https://rpcec.sld.cu/en/trials/RPCEC00000359-En,Pending,0,0,0
Beijing Institute of Biological Products/Wuhan Institute of Biological Products/Sinopharm,WIBP/BIBP vaccines,Phase III,WIBP/BIBP vaccines,Inactivated,45000,≥18,2,Yes,Double-blind,"Bahrain, Jordan, Egypt, UAE",16/07/2020,16/06/2021,NCT04510207,https://clinicaltrials.gov/ct2/show/NCT04510207,Recruiting,0,0,0
Janssen Pharmaceutical Companies,Ad26.COV2.S,Phase III,Janssen Ad26.COV2.S,Vector (non-replicating),44325,≥18,1,Yes,Double-blind,"USA, Argentina, Brazil, others",07/09/2020,22/01/2021,NCT04505722,https://clinicaltrials.gov/ct2/show/NCT04505722,"Active, not recruiting",0,0,0
Instituto Finlay de Vacunas (peptide #2),FINLAY-FR-2/Soberana 02,Phase III,Instituto Finlay de Vacunas FINLAY-FR-2/Soberana 02,Protein subunit,44010,19–80,2 or 3,Yes,Double-blind,Cuba,05/03/2021,07/11/2021,IFV/COR/09,https://rpcec.sld.cu/en/trials/RPCEC00000354-En,Pending,0,0,0
BioNTech/Pfizer/Fosun Pharma,BNT162 (b1/b2),Phase II/III,BioNTech BNT162 (b1/b2),RNA,43998,≥12,2,Yes,"Observer-blind, dose-ranging","USA, Argentina, Brazil, others",29/04/2020,29/10/2021,NCT04368728,https://clinicaltrials.gov/ct2/show/NCT04368728,"Active, not recruiting",0,0,1
CanSino Biological Inc/Beijing Institute of Biotechnology,Ad5-nCoV,Phase III,Cansino Ad5-nCoV,Vector (non-replicating),40000,≥18,1,Yes,Double-blind,"Argentina, Chile, Mexico, others",15/09/2020,30/12/2021,NCT04526990,https://clinicaltrials.gov/ct2/show/NCT04526990,Recruiting,0,0,0
Moderna/NIAID,mRNA-1273,Phase III,Moderna mRNA-1273,RNA,37500,18–26,2,Yes,"Open-label, cross-over",USA,22/03/2021,22/12/2021,NCT04811664,https://clinicaltrials.gov/ct2/show/NCT04811664,Recruiting,0,0,0
CureVac,CVnCoV,Phase II/III,CureVac CVnCoV,RNA,36500,≥18,2,Yes,Observer-blind,"Belgium, Germany, Mexico, others",14/12/2020,05/03/2021,NCT04652102,https://clinicaltrials.gov/ct2/show/NCT04652102,Recruiting,0,0,0
Sanofi Pasteur/GSK,Protein subunit vaccine,Phase III,Sanofi/GSK VAT00002,Protein subunit,34520,≥18,2,Yes,Observer-blind,Kenya,01/12/2020,30/04/2022,PACTR202011523101903,https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=13475,Not yet recruiting,0,0,0
"Institute of Medical Biology,/Chinese Academy of Medical Sciences",Inactivated vaccine,Phase III,CAMS vaccine,Inactivated,34020,≥18,2,Yes,Double-blind,"Brazil, Malaysia",28/01/2021,30/09/2021,NCT04659239,https://clinicaltrials.gov/ct2/show/NCT04659239,Enrolling by invitation,0,0,0
Gamaleya Research Institute,Gam-COVID-Vac/Sputnik V,Phase III,Gamaleya Gam-COVID-Vac/Sputnik V,Vector (non-replicating),33758,≥18,2,Yes,Double-blind,Russia,07/09/2020,01/05/2021,NCT04530396,https://clinicaltrials.gov/ct2/show/NCT04530396,"Active, not recruiting",0,0,0
University of Oxford/AstraZeneca,ChAdOx1-S,Phase III,Oxford ChAdOx1-S,Vector (non-replicating),32459,≥18,2,Yes,Double-blind,"USA, Argentina, Chile, others",28/08/2020,16/03/2021,NCT04516746,https://clinicaltrials.gov/ct2/show/NCT04516746,"Active, not recruiting",0,0,0
Medicago Inc,CoVLP,Phase II/III,Medicago CoVLP,Virus-like particle,30918,≥18,2,Yes,Observer-blind,"USA, Canada",19/11/2020,31/12/2021,NCT04636697,https://clinicaltrials.gov/ct2/show/NCT04636697,Recruiting,0,0,0
Moderna/NIAID,mRNA-1273,Phase III,Moderna mRNA-1273,RNA,30420,≥18,2,Yes,Observer-blind,USA,27/07/2020,27/10/2022,NCT04470427,https://clinicaltrials.gov/ct2/show/NCT04470427,"Active, not recruiting",0,0,0
Janssen Pharmaceutical Companies,Ad26.COV2.S,Phase III,Janssen Ad26.COV2.S,Vector (non-replicating),30000,≥18,2,Yes,Double-blind,"USA, Belgium, Brazil, others",16/11/2020,10/05/2022,NCT04614948,https://clinicaltrials.gov/ct2/show/NCT04614948,Recruiting,0,0,0
Novavax,NVX-CoV2373,Phase III,Novavax NVX-CoV2373,Protein subunit,30000,≥18,2,Yes,Observer-blind,"USA, Mexico, Puerto Rico",27/12/2020,31/03/2021,NCT04611802,https://clinicaltrials.gov/ct2/show/NCT04611802,"Active, not recruiting",0,0,0
Sinovac,CoronaVac,Phase IV,Sinovac CoronaVac,Inactivated,30000,≥18,2,Yes,Stepped-wedge clusters,Brazil,17/02/2021,31/05/2021,NCT04747821,https://clinicaltrials.gov/ct2/show/NCT04747821,Enrolling by invitation,0,0,0
Anhui Zhifei Longcom Biopharmaceutical/Chinese Academy of Sciences,ZF2001,Phase III,AZLB ZF2001,Protein subunit,29000,≥18,Unclear,Yes,Double-blind,"China, Ecuador, Indonesia, others",16/12/2020,30/04/2022,NCT04646590,https://clinicaltrials.gov/ct2/show/NCT04646590,Recruiting,0,0,0
Bharat Biotech/ICMR/National Institute of Virology,Covaxin,Phase III,Bharat Covaxin,Inactivated,25800,≥18,2,Yes,Double-blind,India,16/11/2020,08/01/2021,NCT04641481,https://clinicaltrials.gov/ct2/show/NCT04641481,"Active, not recruiting",0,0,0
Clover Biopharmaceuticals Inc/GSK/Dynavax,SCB-2019,Phase II/III,Clover SCB-2019,Protein subunit,22000,≥18,2,Yes,Double-blind,"Belgium, Brazil, Colombia, others",01/03/2021,31/07/2022,NCT04672395,https://clinicaltrials.gov/ct2/show/NCT04672395,Not yet recruiting,0,0,0
Shifa Pharmed,Inactivated vaccine,Phase II/III,Shifa Pharmed vaccine,Inactivated,20280,18–75,2,Yes,Double-blind,Iran,14/03/2021,,IRCT20201202049567N3,https://en.irct.ir/trial/54881,Recruiting,0,0,0
Novavax,NVX-CoV2373,Phase III,Novavax NVX-CoV2373,Protein subunit,15000,18–84,2,Yes,Double-blind,UK,28/09/2020,31/01/2021,NCT04583995,https://clinicaltrials.gov/ct2/show/NCT04583995,Recruiting,0,0,0
Sinovac,CoronaVac,Phase III,Sinovac CoronaVac,Inactivated,13000,18–59,2,Yes,Double-blind,Turkey,14/09/2020,15/02/2021,NCT04582344,https://clinicaltrials.gov/ct2/show/NCT04582344,Recruiting,0,0,0
Sinovac,CoronaVac,Phase III,Sinovac CoronaVac,Inactivated,12688,≥18,2,Yes,Double-blind,Brazil,21/07/2020,17/12/2020,NCT04456595,https://clinicaltrials.gov/ct2/show/NCT04456595,"Active, not recruiting",0,0,0
University of Oxford/AstraZeneca,ChAdOx1-S,Phase II/III,Oxford ChAdOx1-S,Vector (non-replicating),12390,≥5,1 or 2,Yes,Single-blind,UK,28/05/2020,30/09/2021,NCT04400838,https://clinicaltrials.gov/ct2/show/NCT04400838,Recruiting,0,0,1
ReiThera/Leukocare/Univercells,GRAd-COV2,Phase II/III,ReiThera GRAd-COV2,Vector (non-replicating),10300,≥18,1 or 2,Yes,"Observer-blind, dose-ranging",Italy,15/03/2021,30/05/2021,NCT04791423,https://clinicaltrials.gov/ct2/show/NCT04791423,Not yet recruiting,0,0,0
University of Oxford/AstraZeneca,ChAdOx1-S,Phase III,Oxford ChAdOx1-S,Vector (non-replicating),10300,≥18,1 or 2,Yes,Single-blind,Brazil,02/06/2020,30/09/2021,NCT04536051,https://clinicaltrials.gov/ct2/show/NCT04536051,Recruiting,0,0,0
Sinovac,CoronaVac,Phase IV,Sinovac CoronaVac,Inactivated,10156,18–49,2,No,Open-label,Brazil,18/03/2021,30/06/2021,NCT04789356,https://clinicaltrials.gov/ct2/show/NCT04789356,Recruiting,0,0,0
BioNTech/Pfizer/Fosun Pharma/Moderna/NIAID/University of Oxford/AstraZeneca,BNT162/mRNA-1273/ChAdOx1-S,Phase IV,BNT162/mRNA-1273/ChAdOx1-S,RNA/Vector (non-replicating),10000,≥18,≥1,No,Open-label,Denmark,08/02/2021,31/12/2024,NCT04760132,https://clinicaltrials.gov/ct2/show/NCT04760132,Recruiting,0,0,0
Covaxx/United Biomedical Inc,UB-612,Phase II/III,Covaxx UB-612,Protein subunit,7320,≥18,2,Yes,Double-blind,Pending,01/02/2021,22/03/2023,NCT04683224,https://clinicaltrials.gov/ct2/show/NCT04683224,Not yet recruiting,0,0,0
Moderna/NIAID,mRNA-1273,Phase II/III,Moderna mRNA-1273,RNA,6750,0.5–11,2,Partial,"Open-label (A), observer-blind (B), dose-ranging",USA,15/03/2021,10/06/2023,NCT04796896,https://clinicaltrials.gov/ct2/show/NCT04796896,Recruiting,0,0,1
Beijing Institute of Biological Products/Wuhan Institute of Biological Products/Sinopharm,WIBP/BIBP vaccines,Phase III,WIBP/BIBP vaccines,Inactivated,6000,18–60,2,Yes,Double-blind,Peru,10/09/2020,31/12/2020,NCT04612972,https://clinicaltrials.gov/ct2/show/NCT04612972,Recruiting,0,0,0
Gamaleya Research Institute,Gam-COVID-Vac/Sputnik V,Phase III,Gamaleya Gam-COVID-Vac/Sputnik V,Vector (non-replicating),6000,≥18,1,Yes,Double-blind,Russia,19/02/2021,31/12/2021,NCT04741061,https://clinicaltrials.gov/ct2/show/NCT04741061,Recruiting,0,0,0
BioNTech/Pfizer/Fosun Pharma,BNT162 (b2),Phase I/II/III,BioNTech BNT162 (b2),RNA,4644,0.5–11,2,No,"Open-label (phase I), observer-blind (phase II/III), dose-ranging",USA,24/03/2021,01/03/2022,NCT04816643,https://clinicaltrials.gov/ct2/show/NCT04816643,Recruiting,0,0,1
Novavax,NVX-CoV2373,Phase II,Novavax NVX-CoV2373,Protein subunit,4400,18–84,2,Yes,Observer-blind,South Africa,17/08/2020,30/11/2021,NCT04533399,https://clinicaltrials.gov/ct2/show/NCT04533399,Recruiting,0,0,0
BioNTech/Pfizer/Fosun Pharma,BNT162 (b2),Phase II/III,BioNTech BNT162 (b2),RNA,4000,≥18 (pregnant),2,Yes,Observer-blind,USA,16/02/2021,27/06/2022,NCT04754594,https://clinicaltrials.gov/ct2/show/NCT04754594,Recruiting,0,1,0
Moderna/NIAID,mRNA-1273,Phase IV,Moderna mRNA-1273,RNA,4000,Any,2,Yes,Cluster randomised,Canada,15/04/2021,30/09/2021,NCT04818736,https://clinicaltrials.gov/ct2/show/NCT04818736,Not yet recruiting,0,0,0
"West China Hospital,/Sichuan University",Protein subunit vaccine,Phase II,West China Hospital Protein subunit vaccine,Protein subunit,4000,18–85,3,Yes,Double-blind,China,01/02/2021,15/05/2021,NCT04718467,https://clinicaltrials.gov/ct2/show/NCT04718467,Not yet recruiting,0,0,0
Covaxx/United Biomedical Inc,UB-612,Phase II,Covaxx UB-612,Protein subunit,3850,12–85,2,Yes,Observer-blind,Taiwan,30/01/2021,30/06/2021,NCT04773067,https://clinicaltrials.gov/ct2/show/NCT04773067,Recruiting,0,0,1
Medigen Vaccine Biologics Corporation/NAID/Dynavax,MVC-COV1901,Phase II,Medigen MVC-COV1901,Protein subunit,3700,≥20,2,Yes,Double-blind,"Taiwan, Vietnam",30/12/2020,30/06/2021,NCT04695652,https://clinicaltrials.gov/ct2/show/NCT04695652,"Active, not recruiting",0,0,0
Beijing Institute of Biological Products/Sinopharm,BBIBP-CorV,Phase III,BIBP BBIBP-CorV,Inactivated,3000,18–85,2,Yes,Double-blind,Argentina,16/09/2020,01/12/2021,NCT04560881,https://clinicaltrials.gov/ct2/show/NCT04560881,"Active, not recruiting",0,0,0
Moderna/NIAID,mRNA-1273,Phase II/III,Moderna mRNA-1273,RNA,3000,12–17,2,Yes,Observer-blind,USA,09/12/2020,30/06/2022,NCT04649151,https://clinicaltrials.gov/ct2/show/NCT04649151,"Active, not recruiting",0,0,1
Research Institute for/Biological Safety Problems (inactivated),QazCovid-in,Phase III,RIBSP QazCovid-in,Inactivated,3000,≥18,2,Yes,Single-blind,Kazakhstan,25/12/2020,31/03/2021,NCT04691908,https://clinicaltrials.gov/ct2/show/NCT04691908,"Active, not recruiting",0,0,0
Vector Institute (peptide),EpiVacCorona,Phase III,Vector Institute EpiVacCorona,Protein subunit,3000,≥18,2,Yes,Double-blind,Russia,18/11/2020,31/08/2021,NCT04780035,https://clinicaltrials.gov/ct2/show/NCT04780035,"Active, not recruiting",0,0,0
CureVac,CVnCoV,Phase III,CureVac CVnCoV,RNA,2520,≥18,2,Yes,Observer-blind,Germany,23/12/2020,30/06/2021,NCT04674189,https://clinicaltrials.gov/ct2/show/NCT04674189,Recruiting,0,0,0
Sinovac,CoronaVac,Phase III,Sinovac CoronaVac,Inactivated,2300,≥18,2,Yes,Open-label,Chile,27/11/2020,31/01/2022,NCT04651790,https://clinicaltrials.gov/ct2/show/NCT04651790,Recruiting,0,0,0
University of Oxford/AstraZeneca,ChAdOx1-S,Not specified,Oxford ChAdOx1-S,Vector (non-replicating),2200,18–60 (cirrhosis),2,No,Open-label,India,19/03/2021,19/03/2022,NCT04794946,https://clinicaltrials.gov/ct2/show/NCT04794946,Recruiting,0,0,0
University of Oxford/AstraZeneca,ChAdOx1-S,Phase I/II,Oxford ChAdOx1-S,Vector (non-replicating),2130,18–65,1 or 2,Yes,Double-blind,South Africa,24/06/2020,31/12/2020,NCT04444674,https://clinicaltrials.gov/ct2/show/NCT04444674,"Active, not recruiting",0,0,0
Beijing Institute of Biological Products/Sinopharm,BBIBP-CorV,Phase I/II,BIBP BBIBP-CorV,Inactivated,2128,≥3,Up to 3,Yes,"Double-blind, dose-ranging",China,28/04/2020,28/11/2021,ChiCTR2000032459,http://www.chictr.org.cn/historyversionpuben.aspx?regno=ChiCTR2000032459,Recruiting,0,0,1
Sinovac,CoronaVac,Phase IV,Sinovac CoronaVac,Inactivated,2067,≥18 (autoimmune),2,No,Open-label,Brazil,09/02/2021,31/12/2021,NCT04754698,https://clinicaltrials.gov/ct2/show/NCT04754698,Recruiting,0,0,0
Gamaleya Research Institute,Gam-COVID-Vac/Sputnik V,Phase III,Gamaleya Gam-COVID-Vac/Sputnik V,Vector (non-replicating),2000,≥18,2,Yes,Double-blind,Venezuala,01/11/2020,31/10/2021,NCT04642339,https://clinicaltrials.gov/ct2/show/NCT04642339,Not yet recruiting,0,0,0
Sinovac,CoronaVac,Phase III,Sinovac CoronaVac,Inactivated,1620,18–59,2,Yes,Observer-blind,Indonesia,10/08/2020,09/01/2021,NCT04508075,https://clinicaltrials.gov/ct2/show/NCT04508075,"Active, not recruiting",0,0,0
Gamaleya Research Institute,Gam-COVID-Vac/Sputnik V,Phase II/III,Gamaleya Gam-COVID-Vac/Sputnik V,Vector (non-replicating),1600,≥18,2,Yes,Double-blind,India,30/11/2020,30/08/2021,NCT04640233,https://clinicaltrials.gov/ct2/show/NCT04640233,Recruiting,0,0,0
University of Oxford/AstraZeneca,ChAdOx1-S,Phase II/III,Oxford ChAdOx1-S,Vector (non-replicating),1600,≥18,2,Yes,Observer-blind,India,24/08/2020,24/03/2021,CTRI/2020/08/027170,http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=46186&EncHid=&userName=covid-19%20vaccine,"Active, not recruiting",0,0,0
BioNTech/Pfizer/Fosun Pharma,BNT162 (b2),Phase III,BioNTech BNT162 (b2),RNA,1530,12–50,2,Yes,"Observer-blind, dose-ranging",USA,15/02/2021,11/05/2021,NCT04713553,https://clinicaltrials.gov/ct2/show/NCT04713553,Recruiting,0,0,1
Novavax,NVX-CoV2373,Phase I/II,Novavax NVX-CoV2373,Protein subunit,1419,18–84,1 or 2,Yes,"Double-blind, dose-ranging","Australia, USA",25/05/2020,01/12/2020,NCT04368988,https://clinicaltrials.gov/ct2/show/NCT04368988,"Active, not recruiting",0,0,0
Wuhan Institute of Biological Products/Sinopharm,WIBP vaccine ,Phase I/II,WIBP vaccine ,Inactivated,1264,≥6,Up to 3,Yes,"Double-blind, dose-ranging",China,11/04/2020,10/11/2021,ChiCTR2000031809,http://www.chictr.org.cn/historyversionpuben.aspx?regno=ChiCTR2000031809,Pending,0,0,1
Sinovac,CoronaVac,Phase IV,Sinovac CoronaVac,Inactivated,1200,≥18,2,No,Open-label,Brazil,01/02/2021,31/07/2021,NCT04756830,https://clinicaltrials.gov/ct2/show/NCT04756830,Not yet recruiting,0,0,0
Beijing Institute of Biological Products/Sinopharm,BBIBP-CorV,Phase IV,BIBP BBIBP-CorV,Inactivated,1152,≥18,2,Yes,Single-blind,China,23/02/2021,31/10/2021,NCT04790851,https://clinicaltrials.gov/ct2/show/NCT04790851,Recruiting,0,0,0
BioNTech/Pfizer/Fosun Pharma,BNT162 (b2),Phase III,BioNTech BNT162 (b2),RNA,1100,18–55,2,Yes,Observer-blind,USA,01/04/2021,30/05/2021,NCT04816669,https://clinicaltrials.gov/ct2/show/NCT04816669,Not yet recruiting,0,0,0
University of Oxford/AstraZeneca,ChAdOx1-S,Phase I/II,Oxford ChAdOx1-S,Vector (non-replicating),1090,18–55,1 or 2,Yes,Single-blind,UK,23/04/2020,31/10/2021,NCT04324606,https://clinicaltrials.gov/ct2/show/NCT04324606,"Active, not recruiting",0,0,0
Janssen Pharmaceutical Companies,Ad26.COV2.S,Phase I/II,Janssen Ad26.COV2.S,Vector (non-replicating),1085,≥18,1 or 2,Yes,"Double-blind, dose-ranging","USA, Belgium",15/07/2020,03/12/2021,NCT04436276,https://clinicaltrials.gov/ct2/show/NCT04436276,"Active, not recruiting",0,0,0
Zydus Cadila Healthcare Limited (DNA),ZyCoV-D,Phase I/II,Zydus Cadila ZyCoV-D,DNA,1048,18–55,3,Yes,Double-blind,India,13/07/2020,13/07/2021,CTRI/2020/07/026352,http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=45306&EncHid=&userName=Zydus,"Active, not recruiting",0,0,0
Israel Institute for Biological Research/Weizmann Institute of Science,rVSV-SARS-CoV-2-S,Phase I/II,IIBR rVSV-SARS-CoV-2-S,Vector (replicating),1040,18–85,1 or 2,Yes,"Double-blind, dose-ranging",Israel,28/10/2020,01/05/2021,NCT04608305,https://clinicaltrials.gov/ct2/show/NCT04608305,Recruiting,0,0,0
Sinovac,CoronaVac,Phase III,Sinovac CoronaVac,Inactivated,1040,≥18,2,Yes,Double-blind,China,31/10/2020,28/11/2020,NCT04617483,https://clinicaltrials.gov/ct2/show/NCT04617483,Recruiting,0,0,0
Gamaleya Research Institute,Gam-COVID-Vac/Sputnik V,Phase III,Gamaleya Gam-COVID-Vac/Sputnik V,Vector (non-replicating),1000,≥18,2,Yes,Double-blind,UAE,01/12/2020,31/08/2021,NCT04656613,https://clinicaltrials.gov/ct2/show/NCT04656613,Not yet recruiting,0,0,0
Shenzhen Kangtai Biological Products Co Ltd,Inactivated vaccine,Phase II,Shenzhen Kangtai vaccine,Inactivated,1000,≥18,2 or 3,Yes,"Double-blind, dose-confirmation",China,27/10/2020,30/06/2021,NCT04756323,https://clinicaltrials.gov/ct2/show/NCT04756323,"Active, not recruiting",0,0,0
"West China Hospital,/Sichuan University",Protein subunit vaccine,Phase II,West China Hospital Protein subunit vaccine,Protein subunit,960,18–85,2 or 3,Yes,Double-blind,China,17/11/2020,18/02/2021,NCT04640402,https://clinicaltrials.gov/ct2/show/NCT04640402,Recruiting,0,0,0
BioNTech/Pfizer/Fosun Pharma,BNT162 (b2),Phase II,BioNTech BNT162 (b1/b2),RNA,950,18–85,2,Yes,Observer-blind,China,04/12/2020,31/12/2022,NCT04649021,https://clinicaltrials.gov/ct2/show/NCT04649021,"Active, not recruiting",0,0,0
"Institute of Medical Biology,/Chinese Academy of Medical Sciences",Inactivated vaccine,Phase I/II,CAMS vaccine,Inactivated,942,18–59,2,Yes,"Double-blind, dose-ranging",China,15/05/2020,30/09/2020,NCT04412538,https://clinicaltrials.gov/ct2/show/NCT04412538,Recruiting,0,0,0
Medicago Inc,CoVLP,Phase II,Medicago CoVLP,Virus-like particle,918,≥18,2,Yes,Observer-blind,USA,11/12/2020,31/12/2021,NCT04662697,https://clinicaltrials.gov/ct2/show/NCT04662697,Not yet recruiting,0,0,0
Instituto Finlay de Vacunas (peptide #2),FINLAY-FR-2/Soberana 02A,Phase II,Instituto Finlay de Vacunas FINLAY-FR-2/Soberana 02A,Protein subunit,910,19–80,2,Yes,Double-blind,Cuba,21/12/2020,12/03/2021,IFV/COR/08,https://rpcec.sld.cu/en/trials/RPCEC00000347-En,Pending,0,0,0
Anhui Zhifei Longcom Biopharmaceutical/Chinese Academy of Sciences,ZF2001,Phase II,AZLB ZF2001,Protein subunit,900,18–59,2 or 3,Yes,Double-blind,China,12/07/2020,15/09/2021,NCT04466085,https://clinicaltrials.gov/ct2/show/NCT04466085,Recruiting,0,0,0
BioNTech/Pfizer/Fosun Pharma/Sinovac/University of Oxford/AstraZeneca,BNT162/CoronaVac/ChAdOx1-S,Phase IV,BNT162/CoronaVac/ChAdOx1-S,RNA/Inactivated/Vector (non-replicating),900,≥18 (chronic liver disease),2,No,Open-label,Hong Kong,15/03/2021,31/12/2021,NCT04775069,https://clinicaltrials.gov/ct2/show/NCT04775069,Not yet recruiting,0,0,0
BioNTech/Pfizer/Fosun Pharma/Sinovac/University of Oxford/AstraZeneca,BNT162/CoronaVac/ChAdOx1-S,Phase III,BNT162/CoronaVac/ChAdOx1-S,RNA/Inactivated/Vector (non-replicating),900,≥11,2,No,Open-label,Hong Kong,21/03/2021,31/03/2025,NCT04800133,https://clinicaltrials.gov/ct2/show/NCT04800133,Not yet recruiting,0,0,1
BioNTech/Pfizer/Fosun Pharma/University of Oxford/AstraZeneca,BNT162/ChAdOx1-S,Phase II,BNT162/ChAdOx1-S prime-boost,RNA/Vector (non-replicating),820,≥50,2,Yes,Single-blind,UK,08/02/2021,05/11/2022,ISRCTN69254139,https://www.isrctn.com/ISRCTN69254139,No longer recruiting,1,0,0
VBI Vaccines Inc,VBI-2902a,Phase I/II,VBI Vaccines VBI-2902a,VLP,780,≥18,2,Yes,"Observer-blind, dose-ranging",Canada,01/03/2021,30/06/2022,NCT04773665,https://clinicaltrials.gov/ct2/show/NCT04773665,Not yet recruiting,0,0,0
Bharat Biotech/ICMR/National Institute of Virology,Covaxin,Phase I/II,Bharat Covaxin,Inactivated,755,12–65,2,Yes,Double-blind,India,15/07/2020,31/07/2020,NCT04471519,https://clinicaltrials.gov/ct2/show/NCT04471519,"Active, not recruiting",0,0,1
Sinovac,CoronaVac,Phase I/II,Sinovac CoronaVac,Inactivated,744,18–59,2,Yes,"Double-blind, dose-ranging",China,16/04/2020,10/07/2020,NCT04352608,https://clinicaltrials.gov/ct2/show/NCT04352608,"Active, not recruiting",0,0,0
Sanofi Pasteur/GSK,Protein subunit vaccine,Phase II,Sanofi/GSK VAT00002,Protein subunit,722,≥18,2,Yes,Double-blind,"USA, Honduras",24/02/2021,30/04/2022,NCT04762680,https://clinicaltrials.gov/ct2/show/NCT04762680,"Active, not recruiting",0,0,0
University of Hong Kong/Jiangsu Provincial CDC/Beijing Wantai Biological Pharmacy/Xiamen University,DelNS1-nCoV-RBD,Phase II,BWBP DelNS1-nCoV-RBD,Vector (replicating),720,≥18,2,Yes,Double-blind,China,17/11/2020,17/12/2021,ChiCTR2000039715,http://www.chictr.org.cn/historyversionpuben.aspx?regno=ChiCTR2000039715,Recruiting,0,0,0
CureVac,CVnCoV,Phase II,CureVac CVnCoV,RNA,700,≥18,2,Yes,"Observer-blind, dose-confirmation","Brazil, Panama, Peru",17/08/2020,17/09/2021,PER-054-20,https://www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=054-20,Recruiting,0,0,0
CanSino Biological Inc/Beijing Institute of Biotechnology,Ad5-nCoV,Phase I/II,Cansino Ad5-nCoV,Vector (non-replicating),696,18–84,1 or 2,Yes,"Double-blind, dose-ranging",Canada,01/08/2020,20/12/2021,NCT04398147,https://clinicaltrials.gov/ct2/show/NCT04398147,Not yet recruiting,0,0,0
Instituto Finlay de Vacunas (peptide #1),FINLAY-FR-1/Soberana 01,Phase I/II,Instituto Finlay de Vacunas FINLAY-FR-1/Soberana 01,Protein subunit,676,19–80,2,Yes,Double-blind,Cuba,24/08/2020,11/01/2021,IFV/COR/04,https://rpcec.sld.cu/en/trials/RPCEC00000332-En,Recruiting,0,0,0
CureVac,CVnCoV,Phase II,CureVac CVnCoV,RNA,674,≥18,2,Yes,"Observer-blind, dose-confirmation","Panama, Peru",28/09/2020,09/11/2021,NCT04515147,https://clinicaltrials.gov/ct2/show/NCT04515147,"Active, not recruiting",0,0,0
Moderna/NIAID,mRNA-1273/mRNA-1273.351,Phase II,Moderna mRNA-1273/mRNA-1273.351,RNA,660,≥18,2,Yes,"Observer-blind (part A/B), open-label (part C), dose-confirmation",USA,29/05/2020,31/03/2021,NCT04405076,https://clinicaltrials.gov/ct2/show/NCT04405076,"Active, not recruiting",0,0,0
Inovio Pharmaceuticals/International Vaccine Institute,INO-4800,Phase II,Inovio INO-4800,DNA,640,18–85,2,Yes,"Double-blind, dose-ranging",China,02/12/2020,31/01/2020,ChiCTR2000040146,http://www.chictr.org.cn/historyversionpuben.aspx?regno=ChiCTR2000040146,Complete,0,0,0
Nanogen Biopharmaceutical,Nanocovax,Phase I/II,Nanogen Nanocovax,Protein subunit,620,12–75,2,Yes,"Open-label (phase I), double-blind (phase II), dose-ranging",Vietnam,10/12/2020,10/06/2021,NCT04683484,https://clinicaltrials.gov/ct2/show/NCT04683484,Recruiting,0,0,1
Arcturus/Duke-NUS,LUNAR-COV19/ARCT-021,Phase II,Arcturus ARCT-021,RNA,600,≥18,1 or 2,Yes,"Observer-blind, dose-ranging","USA, Singapore",07/01/2021,30/04/2022,NCT04668339,https://clinicaltrials.gov/ct2/show/NCT04668339,"Active, not recruiting",0,0,0
Wuhan Institute of Biological Products/Sinopharm,WIBP vaccine ,Phase III,WIBP vaccine,Inactivated,600,≥18,2,Yes,Double-blind,Morocco,02/09/2020,31/12/2020,ChiCTR2000039000,http://www.chictr.org.cn/historyversionpuben.aspx?regno=ChiCTR2000039000,Recruiting,0,0,0
Sinovac,CoronaVac,Phase I/II,Sinovac CoronaVac,Inactivated,552,3–17,2,Yes,Double-blind,China,31/10/2020,28/02/2021,NCT04551547,https://clinicaltrials.gov/ct2/show/NCT04551547,Recruiting,0,0,1
Janssen Pharmaceutical Companies,Ad26.COV2.S,Phase II,Janssen Ad26.COV2.S,Vector (non-replicating),550,≥18,1 or 2,Yes,"Double-blind, dose-ranging","Belgium, USA",28/08/2020,15/12/2021,NCT04535453,https://clinicaltrials.gov/ct2/show/NCT04535453,Recruiting,0,0,0
BioNTech/Pfizer/Fosun Pharma,BNT162 (b2),Phase IV,BioNTech BNT162 (b1/b2),RNA,540,≥18 (immunocompromised),2,No,Open-label,Sweden,23/02/2021,31/12/2022,NCT04780659,https://clinicaltrials.gov/ct2/show/NCT04780659,Recruiting,0,0,0
CanSino Biological Inc/Beijing Institute of Biotechnology,Ad5-nCoV,Phase II,Cansino Ad5-nCoV,Vector (non-replicating),508,18–60,1,Yes,Double-blind,China,12/04/2020,31/01/2021,NCT04341389,https://clinicaltrials.gov/ct2/show/NCT04341389,"Active, not recruiting",0,0,0
CanSino Biological Inc/Beijing Institute of Biotechnology,Ad5-nCoV,Phase III,Cansino Ad5-nCoV,Vector (non-replicating),500,18–85,1,Yes,Double-blind,Russia,11/09/2020,30/05/2021,NCT04540419,https://clinicaltrials.gov/ct2/show/NCT04540419,"Active, not recruiting",0,0,0
Osaka University/AnGes/Takara Bio,AG0302-COVID19,Phase II/III,AnGes AG0302-COVID19,DNA,500,≥18,2,Yes,Double-blind,Japan,23/11/2020,27/05/2021,NCT04655625,https://clinicaltrials.gov/ct2/show/NCT04655625,"Active, not recruiting",0,0,0
CanSino Biological Inc/Beijing Institute of Biotechnology,Ad5-nCoV,Phase II,Cansino Ad5-nCoV,Vector (non-replicating),481,≥6,2,Yes,"Double-blind, dose-ranging",China,24/09/2020,21/08/2021,NCT04566770,https://clinicaltrials.gov/ct2/show/NCT04566770,Recruiting,0,0,1
Anhui Zhifei Longcom Biopharmaceutical/Chinese Academy of Sciences,ZF2001,Phase II,AZLB ZF2001,Protein subunit,480,18–85,2 or 3,Yes,"Double-blind, dose-ranging",China,23/03/2021,30/07/2021,NCT04813562,https://clinicaltrials.gov/ct2/show/NCT04813562,Recruiting,0,0,0
Sinovac,CoronaVac,Phase IV,Sinovac CoronaVac,Inactivated,480,18–59,2,Yes,Open-label,China,01/03/2021,31/07/2021,NCT04801888,https://clinicaltrials.gov/ct2/show/NCT04801888,Not yet recruiting,0,0,0
"Institute of Medical Biology,/Chinese Academy of Medical Sciences",Inactivated vaccine,Phase I/II,CAMS vaccine,Inactivated,471,≥60,2,Yes,Double-blind,China,10/07/2020,30/11/2020,NCT04470609,https://clinicaltrials.gov/ct2/show/NCT04470609,Enrolling by invitation,0,0,0
Government Pharmaceutical Organization/Mahidol University/Icahn School of Medicine,NDV-HXP-S,Phase I/II,GPO NDV-HXP-S,Vector (replicating),460,18–75,2,Yes,"Observer-blind, dose-ranging",Thailand,20/03/2021,30/04/2022,NCT04764422,https://clinicaltrials.gov/ct2/show/NCT04764422,Recruiting,0,0,0
BioNTech/Pfizer/Fosun Pharma,BNT162 (a1/b1/b2/c2),Phase I/II,BioNTech BNT162 (a1/b1/b2/c2),RNA,456,18–85,1 or 2,No,"Open-label, dose-ranging",Germany,23/04/2020,30/04/2023,NCT04380701,https://clinicaltrials.gov/ct2/show/NCT04380701,Recruiting,0,0,0
Sanofi Pasteur/GSK,Protein subunit vaccine,Phase I/II,Sanofi/GSK VAT00002,Protein subunit,440,≥18,1 or 2,Yes,Double-blind,USA,03/09/2020,30/11/2021,NCT04537208,https://clinicaltrials.gov/ct2/show/NCT04537208,"Active, not recruiting",0,0,0
Sinovac,CoronaVac,Phase I/II,Sinovac CoronaVac,Inactivated,422,≥60,2,Yes,"Double-blind, dose-ranging",China,22/05/2020,28/08/2020,NCT04383574,https://clinicaltrials.gov/ct2/show/NCT04383574,"Active, not recruiting",0,0,0
IVAC/Dynavax/PATH,COVIVAC,Phase I/II,IVAC COVIVAC,Inactivated,420,18–75,2,Yes,"Observer-blind, dose-ranging",Vietnam,10/03/2021,30/05/2022,NCT04830800,https://clinicaltrials.gov/ct2/show/NCT04830800,Recruiting,0,0,0
Sanofi Pasteur/Translate Bio,LNP-mRNA vaccine,Phase I/II,Sanofi/Translate VAW00001,RNA,415,≥18,1 or 2,Yes,"Open-label (sentinel), observer-blind (full), dose-ranging",USA,12/03/2021,31/05/2022,NCT04798027,https://clinicaltrials.gov/ct2/show/NCT04798027,Recruiting,0,0,0
Inovio Pharmaceuticals/International Vaccine Institute,INO-4800,Phase II/III,Inovio INO-4800,DNA,401,≥18,2,Yes,"Double-blind, dose-ranging",USA,30/11/2020,30/09/2022,NCT04642638,https://clinicaltrials.gov/ct2/show/NCT04642638,"Active, not recruiting",0,0,0
Janssen Pharmaceutical Companies,Ad26.COV2.S,Phase II,Janssen Ad26.COV2.S,Vector (non-replicating),400,18–45 (pregnant),2,No,"Open-label, dose-ranging","USA, Australia, Brazil, others",12/03/2021,16/01/2023,NCT04765384,https://clinicaltrials.gov/ct2/show/NCT04765384,Not yet recruiting,0,1,0
Medigen Vaccine Biologics Corporation/NAID/Dynavax,MVC-COV1901,Phase II,Medigen MVC-COV1901,Protein subunit,400,≥65,2,Yes,"Double-blind, dose-ranging",Taiwan,01/05/2021,30/09/2021,NCT04822025,https://clinicaltrials.gov/ct2/show/NCT04822025,Not yet recruiting,0,0,0
BioNTech/Pfizer/Fosun Pharma/Moderna/NIAID,BNT162/mRNA-1273,Phase III,BNT162/mRNA-1273,RNA,380,≥18 (immunocompromised),2,Yes,Open-label,Switzerland,01/04/2021,31/07/2022,NCT04805125,https://clinicaltrials.gov/ct2/show/NCT04805125,Not yet recruiting,0,0,0
Beijing Institute of Biological Products/Sinopharm,BBIBP-CorV,Not specified,BIBP BBIBP-CorV,Inactivated,360,18–59 (healthcare workers),2,Yes,Not stated,China,28/09/2020,27/03/2021,ChiCTR2100041704,http://www.chictr.org.cn/showproj.aspx?proj=66464,Complete,0,0,0
Beijing Institute of Biological Products/Sinopharm,BBIBP-CorV,Not specified,BIBP BBIBP-CorV,Inactivated,360,18–59 (airline staff),2,Yes,Not stated,China,28/09/2020,27/03/2021,ChiCTR2100041705,http://www.chictr.org.cn/showproj.aspx?proj=66407,Recruiting,0,0,0
Beijing Institute of Biological Products/Sinopharm,BBIBP-CorV,Not specified,BIBP BBIBP-CorV,Inactivated,360,18–59 (security personnel),2,Yes,Not stated,China,28/09/2020,27/03/2021,ChiCTR2100041706,http://www.chictr.org.cn/historyversionpuben.aspx?regno=ChiCTR2100041706,Recruiting,0,0,0
Biological E Ltd,BECOV,Phase I/II,Biological E Ltd BECOV,Protein subunit,360,18–65,2 or 3,Yes,Open-label,India,16/11/2020,16/01/2022,CTRI/2020/11/029032,http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=48329&EncHid=&userName=covid-19%20vaccine,"Active, not recruiting",0,0,0
GeneOne Life Science,GLS-5310,Phase I/II,GeneOne GLS-5310,DNA,345,19–65,2,Yes,"Double-blind, dose-ranging",Republic of Korea,23/12/2020,31/07/2022,NCT04673149,https://clinicaltrials.gov/ct2/show/NCT04673149,Not yet recruiting,0,0,0
Imperial College London,LNP-nCoVsaRNA,Phase I,Imperial LNP-nCoVsaRNA,RNA,320,18–75,2,Partial,"Open-label (A), observer-blind (B), dose-ranging",UK,16/06/2020,31/07/2021,ISRCTN17072692,http://www.isrctn.com/ISRCTN17072692,No longer recruiting,0,0,0
SK Biosciences,GBP510,Phase I/II,SK Biosciences GBP510,Protein subunit,320,19–85,2,Yes,"Observer-blind, dose-ranging",Republic of Korea,03/02/2021,31/07/2021,NCT04750343,https://clinicaltrials.gov/ct2/show/NCT04750343,Recruiting,0,0,0
BioNTech/Pfizer/Fosun Pharma,BNT162 (b2),Phase II,BioNTech BNT162 (b2),RNA,300,≥18 (history of SARS-CoV-2),1 or 2,No,Open-label,France,08/03/2021,08/08/2021,NCT04824638,https://clinicaltrials.gov/ct2/show/NCT04824638,Recruiting,0,0,0
University of Oxford/AstraZeneca,ChAdOx1-S,Phase II,Oxford ChAdOx1-S,Vector (non-replicating),300,6–17,2,Yes,Single-blind,UK,15/02/2021,30/09/2022,ISRCTN15638344,https://www.isrctn.com/ISRCTN15638344,Recruiting,0,0,1
CureVac,CVnCoV,Phase I,CureVac CVnCoV,RNA,280,18–60,2,Yes,"Open-label (phase I), single-blind (phase II), dose-ranging","Belgium, Germany",18/06/2020,31/12/2021,NCT04449276,https://clinicaltrials.gov/ct2/show/NCT04449276,"Active, not recruiting",0,0,0
EuBiologics Co Ltd,EuCorVac-19,Phase I/II,EuBiologicals EuCorVac-19,Protein subunit,280,19–75,2,Yes,"Observer-blind, dose-ranging",Republic of Korea,23/02/2021,31/03/2022,NCT04783311,https://clinicaltrials.gov/ct2/show/NCT04783311,Recruiting,0,0,0
SpyBiotech/Accelagen Pty/Serum Institute of India,RBD-HBsAg VLP vaccine,Phase I/II,SpyBiotech RBD-HBsAg VLP,Virus-like particle,280,18–79,1 or 2,Yes,"Observer-blind, dose-ranging",Australia,22/08/2020,30/03/2021,ACTRN12620000817943,https://anzctr.org.au/Trial/Registration/TrialReview.aspx?id=380145&isReview=true,Recruiting,0,0,0
Institut Pasteur/Themis/University of Pittsburg/Merck,V591/TMV-083,Phase I/II,Themis V591/TMV-083,Vector (replicating),263,≥18,1 or 2,Yes,"Double-blind, dose-ranging","USA, Austria, Belgium",27/08/2020,05/03/2021,NCT04498247,https://clinicaltrials.gov/ct2/show/NCT04498247,Terminated,0,0,0
SK Biosciences,GBP510,Phase I/II,SK Biosciences GBP510,Protein subunit,260,19–85,2,Yes,"Observer-blind, dose-ranging",Republic of Korea,20/01/2021,31/08/2021,NCT04742738,https://clinicaltrials.gov/ct2/show/NCT04742738,Recruiting,0,0,0
University of Oxford/AstraZeneca,ChAdOx1-S,Phase I/II,Oxford ChAdOx1-S,Vector (non-replicating),256,≥18,1 or 2,Yes,Double-blind,Japan,23/08/2020,15/11/2021,NCT04568031,https://clinicaltrials.gov/ct2/show/NCT04568031,"Active, not recruiting",0,0,0
Erciyes University (inactivated),ERUCOV-VAC,Phase II,Erciyes ERUCOV-VAC,Inactivated,250,18–64,2,Yes,"Double-blind, dose-ranging",Turkey,10/02/2021,30/04/2021,NCT04824391,https://clinicaltrials.gov/ct2/show/NCT04824391,Recruiting,0,0,0
Janssen Pharmaceutical Companies,Ad26.COV2.S,Phase I,Janssen Ad26.COV2.S,Vector (non-replicating),250,≥20,2,Yes,"Double-blind, dose-ranging",Japan,11/08/2020,08/01/2021,NCT04509947,https://clinicaltrials.gov/ct2/show/NCT04509947,"Active, not recruiting",0,0,0
Research Institute for/Biological Safety Problems (inactivated),QazCovid-in,Phase I/II,RIBSP QazCovid-in,Inactivated,244,≥18,1 or 2,Yes,Single-blind,Kazakhstan,19/09/2020,25/11/2020,NCT04530357,https://clinicaltrials.gov/ct2/show/NCT04530357,Completed,0,0,0
IAVI/Merck,V590,Phase I,Merck V590,Vector (replicating),232,≥18,1,Yes,"Double-blind, dose-ranging",USA,29/10/2020,18/02/2021,NCT04569786,https://clinicaltrials.gov/ct2/show/NCT04569786,Terminated,0,0,0
Moderna/NIAID,mRNA-1273,Phase III,Moderna mRNA-1273,RNA,220,≥18 (autoimmune),2,No,Open-label,Canada,11/03/2021,11/03/2022,NCT04806113,https://clinicaltrials.gov/ct2/show/NCT04806113,Recruiting,0,0,0
Anhui Zhifei Longcom Biopharmaceutical/Chinese Academy of Sciences,ZF2001,Phase I,AZLB ZF2001,Protein subunit,216,≥18,2 or 3,Yes,"Double-blind, dose-ranging",China,30/10/2020,07/04/2021,NCT04636333,https://clinicaltrials.gov/ct2/show/NCT04636333,Recruiting,0,0,0
University of Queensland/CSL/Seqirus,aCoV2,Phase I,University of Queensland vaccine,Protein subunit,216,≥18,2,Yes,"Double-blind, dose-ranging",Australia,13/07/2020,31/10/2020,NCT04495933,https://clinicaltrials.gov/ct2/show/NCT04495933,Recruiting,0,0,0
Shionogi,S-268019,Phase I/II,Shionogi S-268019,Protein subunit,214,20–64,2,Yes,Double-blind,Japan,11/12/2020,,jRCT2051200092,https://jrct.niph.go.jp/en-latest-detail/jRCT2051200092,Recruiting,0,0,0
Genexine Consortium,GX-19,Phase I/II,Genexine GX-19,DNA,210,18–50,2,Yes,"Double-blind, dose-ranging",Republic of Korea,17/06/2020,17/03/2021,NCT04445389,https://clinicaltrials.gov/ct2/show/NCT04445389,Recruiting,0,0,0
Moderna/NIAID,mRNA-1273/mRNA-1273.351,Phase I,Moderna mRNA-1273/mRNA-1273.351,RNA,210,≥18,1 or 2,Yes,"Open-label, dose-ranging",USA,29/03/2021,31/08/2022,NCT04785144,https://clinicaltrials.gov/ct2/show/NCT04785144,Recruiting,0,0,0
Moderna/NIAID,mRNA-1273,Phase I/II,Moderna mRNA-1273,RNA,200,≥20,2,Yes,Observer-blind,Japan,21/01/2021,03/03/2022,NCT04677660,https://clinicaltrials.gov/ct2/show/NCT04677660,"Active, not recruiting",0,0,0
Novavax,NVX-CoV2373,Phase I/II,Novavax NVX-CoV2373,Protein subunit,200,≥20,2,Yes,Observer-blind,Japan,24/02/2021,04/04/2022,NCT04712110,https://clinicaltrials.gov/ct2/show/NCT04712110,"Active, not recruiting",0,0,0
Altimmune/University of Alabama at Birmingham,AdCOVID,Phase I,Altimmune AdCOVID,Vector (non-replicating),180,18–55,1 or 2,Yes,"Double-blind, dose-ranging",USA,01/02/2021,28/02/2022,NCT04679909,https://clinicaltrials.gov/ct2/show/NCT04679909,Recruiting,0,0,0
Kentucky Bioprocessing Inc,KBP-COVID-19,Phase I/II,KBP-COVID-19,Protein subunit,180,18–85,2,Yes,"Observer-blind, dose-ranging",USA,30/12/2020,06/05/2021,NCT04473690,https://clinicaltrials.gov/ct2/show/NCT04473690,Recruiting,0,0,0
Medicago Inc,CoVLP,Phase I,Medicago CoVLP,Virus-like particle,180,18–55,2,Yes,"Open-label, dose-ranging",Canada,10/07/2020,12/09/2020,NCT04450004,https://clinicaltrials.gov/ct2/show/NCT04450004,"Active, not recruiting",0,0,0
Moderna/NIAID,mRNA-1273,Phase II,Moderna mRNA-1273,RNA,180,≥18,2,No,Open-label,France,10/02/2021,01/07/2021,NCT04748471,https://clinicaltrials.gov/ct2/show/NCT04748471,Not yet recruiting,0,0,0
Shenzhen Kangtai Biological Products Co Ltd,Inactivated vaccine,Phase I,Shenzhen Kangtai vaccine,Inactivated,180,≥18,2 or 3,Yes,"Double-blind, dose-ranging",China,07/10/2020,30/06/2021,NCT04758273,https://clinicaltrials.gov/ct2/show/NCT04758273,"Active, not recruiting",0,0,0
Aivita Biomedical Inc,AV-COVID-19,Phase I/II,Aivita AV-COVID-19,Other/Unknown,175,≥18,1,No,"Open-label, dose-ranging",USA,01/06/2021,30/11/2021,NCT04386252,https://clinicaltrials.gov/ct2/show/NCT04386252,Not yet recruiting,0,0,0
Bharat Biotech,BBV154,Phase I,Bharat BBV154,Vector (non-replicating),175,18–60,1 or 2,Yes,Double-blind,India,01/03/2021,25/03/2021,NCT04751682,https://clinicaltrials.gov/ct2/show/NCT04751682,"Active, not recruiting",0,0,0
Genexine Consortium,GX-19,Phase I/II,Genexine GX-19,DNA,170,18–55,2,Yes,Double-blind,Republic of Korea,30/12/2020,30/05/2021,NCT04715997,https://clinicaltrials.gov/ct2/show/NCT04715997,Recruiting,0,0,0
Shulan (Hangzhou) Hospital/Guangxi Zhuang Autonomous Region CDC/PLA Academy of Military Sciences/Walvax Biotech,ARCoV,Phase I,PLA-AMS ARCoV,RNA,168,18–80,Unclear,Yes,"Blinding unclear, dose-ranging",China,25/06/2020,31/12/2021,ChiCTR2000034112,http://www.chictr.org.cn/historyversionpuben.aspx?regno=ChiCTR2000034112,Pending,0,0,0
"West China Hospital,/Sichuan University",Protein subunit vaccine,Phase I,West China Hospital Protein subunit vaccine,Protein subunit,168,≥18,2 or 3,Yes,"Double-blind, dose-ranging",China,28/08/2020,28/10/2020,NCT04530656,https://clinicaltrials.gov/ct2/show/NCT04530656?,"Active, not recruiting",0,0,0
Anhui Zhifei Longcom Biopharmaceutical/Chinese Academy of Sciences,ZF2001,Phase I,AZLB ZF2001,Protein subunit,160,18–80,2,Yes,"Double-blind, dose-ranging",New Zealand,01/04/2021,31/07/2021,NCT04818801,https://clinicaltrials.gov/ct2/show/NCT04818801,Not yet recruiting,0,0,0
BioNTech/Pfizer/Fosun Pharma,BNT162 (b2),Phase I/II,BioNTech BNT162 (b2),RNA,160,20–85,2,Yes,Double-blind,Japan,21/10/2020,30/11/2021,NCT04588480,https://clinicaltrials.gov/ct2/show/NCT04588480,"Active, not recruiting",0,0,0
Inovio Pharmaceuticals/International Vaccine Institute,INO-4800,Phase I/II,Inovio INO-4800,DNA,160,19–64,2,Yes,"Open-label (A), double-blind (B), dose-ranging",Republic of Korea,15/07/2020,22/02/2022,NCT04447781,https://clinicaltrials.gov/ct2/show/NCT04447781,Recruiting,0,0,0
Takis/Applied DNA Sciences/Evvivax/Rottapharm Biotech,COVID-eVax,Phase I/II,Takis COVID-eVax,DNA,160,≥18,Unclear,No,"Open-label, dose-ranging",Italy,03/02/2021,,2020-003734-20,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003734-20/IT#E,Ongoing,0,0,0
Takis/Applied DNA Sciences/Evvivax/Rottapharm Biotech,COVID-eVax,Phase I/II,Takis COVID-eVax,DNA,160,18–65,1 or 2,No,"Open-label, dose-ranging",Italy,25/02/2021,30/09/2021,NCT04788459,https://clinicaltrials.gov/ct2/show/NCT04788459,Recruiting,0,0,0
Valneva/Dynavax,VLA2001,Phase I/II,Valneva VLA2001,Inactivated,153,18–55,2,Yes,"Open-label (phase I), double-blind (phase II), dose-ranging",UK,16/12/2020,26/02/2021,NCT04671017,https://clinicaltrials.gov/ct2/show/NCT04671017,"Active, not recruiting",0,0,0
University of Tokyo/Daiichi-Sankyo,DS-5670a,Phase I/II,Daiichi-Sankyo DS-5670a,RNA,152,20–74,2,Yes,"Double-blind, dose-ranging",Japan,15/03/2021,31/07/2022,NCT04821674,https://clinicaltrials.gov/ct2/show/NCT04821674,Recruiting,0,0,0
BioNet Asia,COVIGEN,Phase I,BioNet Asia COVIGEN,DNA,150,18–75,2,Yes,"Double-blind, dose-ranging",Australia,15/02/2021,30/06/2022,NCT04742842,https://clinicaltrials.gov/ct2/show/NCT04742842,Not yet recruiting,0,0,0
Cellid Co Ltd/IAVI,AdCLD-CoV19,Phase I/II,Cellid AdCLD-CoV19,Vector (replicating),150,19–64,1,Yes,"Open-label, dose-ranging",Republic of Korea,29/12/2020,31/03/2021,NCT04666012,https://clinicaltrials.gov/ct2/show/NCT04666012,Recruiting,0,0,0
Clover Biopharmaceuticals Inc/GSK/Dynavax,SCB-2019,Phase I,Clover SCB-2019,Protein subunit,150,18–75,2,Yes,"Double-blind, dose-ranging",Australia,19/06/2020,16/10/2020,NCT04405908,https://clinicaltrials.gov/ct2/show/NCT04405908,"Active, not recruiting",0,0,0
Zydus Cadila Healthcare Limited (DNA),ZyCoV-D,Phase I/II,Zydus Cadila ZyCoV-D,DNA,150,18–60,3,Yes,Double-blind,India,19/03/2021,19/09/2021,CTRI/2021/03/032051,http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=53226&EncHid=&userName=covid%20vaccine,Recruiting,0,0,0
CanSino Biological Inc/PLA Academy of Military Sciences,Ad5-nCoV,Phase I,PLA Ad5-nCoV,Vector (non-replicating),149,≥18,1 or 2,No,"Open-label, dose-ranging",China,29/09/2020,31/12/2020,NCT04552366,https://clinicaltrials.gov/ct2/show/NCT04552366,"Active, not recruiting",0,0,0
BioNTech/Pfizer/Fosun Pharma,BNT162 (b1),Phase I,BioNTech BNT162,RNA,144,18–85,2,Yes,Double-blind,China,28/07/2020,30/09/2020,NCT04523571,https://clinicaltrials.gov/ct2/show/NCT04523571,"Active, not recruiting",0,0,0
Organization of Defensive/Innovation and Research,FAKHRAVAC,Phase I,ODIR FAKHRAVAC,Inactivated,135,18–55,2,Yes,"Double-blind, dose-ranging",,10/03/2021,09/04/2021,IRCT20210206050259N1,https://en.irct.ir/trial/54133,Recruiting,0,0,0
Razi Vaccine and Serum/Research Institute,Razi Cov Pars,Phase I,Razi Cov Pars,Protein subunit,133,18–55,3,Yes,"Double-blind, dose-ranging",Iran,29/01/2021,10/03/2021,IRCT20201214049709N1,https://www.irct.ir/trial/52975,Complete,0,0,0
Center for Genetic Engineering/and Biotechnology (peptide #1),CIGB-66,Phase I/II,CIGB CIGB-66,Protein subunit,132,19–54,3,Yes,Double-blind,Cuba,07/12/2020,31/05/2021,RPCEC00000346,https://rpcec.sld.cu/en/trials/RPCEC00000346-En,Pending,0,0,0
Akston Biosciences/University Medical Center Groningen,AKS-452,Phase I/II,Akston AKS-452,Protein subunit,130,18–55,Unclear,No,"Open-label, dose-ranging",Netherlands,18/01/2021,30/04/2021,NCT04681092,https://clinicaltrials.gov/ct2/show/NCT04681092,Not yet recruiting,0,0,0
Gritstone Oncology,ChAdV68-S/SAM-LNP-S,Phase I,Gritstone ChAdV68-S/SAM-LNP-S,Vector (non-replicating),130,≥18,2,Yes,"Open-label, dose-ranging",USA,25/03/2021,19/09/2022,NCT04776317,https://clinicaltrials.gov/ct2/show/NCT04776317,Recruiting,0,0,0
Meissa Vaccines,MV-014-212,Phase I,Meissa MV-014-212,Vector (replicating),130,18–69,1 or 2,No,"Open-label, dose-ranging",USA,31/03/2021,31/10/2022,NCT04798001,https://clinicaltrials.gov/ct2/show/NCT04798001,Not yet recruiting,0,0,0
City of Hope,COH04S1,Phase I,City of Hope COH04S1,Vector (replicating),129,18–55,1 or 2,Yes,"Double-blind, dose-ranging",USA,11/12/2020,10/11/2022,NCT04639466,https://clinicaltrials.gov/ct2/show/NCT04639466,Recruiting,0,0,0
Moderna/NIAID,mRNA-1283/mRNA-1273,Phase I,Moderna mRNA-1283/mRNA-1273,RNA,125,18–55,2,Yes,"Observer-blind, dose-ranging",USA,11/03/2021,13/04/2022,NCT04813796,https://clinicaltrials.gov/ct2/show/NCT04813796,Recruiting,0,0,0
Bharat Biotech/ICMR/National Institute of Virology,Covaxin,Phase I/II,Bharat Covaxin,Inactivated,124,12–65,2,Yes,"Open-label, dose-ranging",India,08/09/2020,08/05/2021,CTRI/2020/09/027674,http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=46312&EncHid=&userName=vaccine,"Active, not recruiting",0,0,1
Inovio Pharmaceuticals/International Vaccine Institute,INO-4800,Phase I,Inovio INO-4800,DNA,120,≥18,1 or 2,No,"Open-label, dose-ranging",USA,03/04/2020,31/01/2022,NCT04336410,https://clinicaltrials.gov/ct2/show/NCT04336410,"Active, not recruiting",0,0,0
Moderna/NIAID,mRNA-1273,Phase I,Moderna mRNA-1273,RNA,120,≥18,2,No,"Open-label, dose-ranging",USA,16/03/2020,22/11/2022,NCT04283461,https://clinicaltrials.gov/ct2/show/NCT04283461,"Active, not recruiting",0,0,0
Shulan (Hangzhou) Hospital/Guangxi Zhuang Autonomous Region CDC/PLA Academy of Military Sciences/Walvax Biotech,ARCoV,Phase I,PLA-AMS ARCoV,RNA,120,18–59,Unclear,Yes,"Double-blind, dose-ranging",China,28/10/2020,31/12/2021,ChiCTR2000039212,http://www.chictr.org.cn/historyversionpuben.aspx?regno=ChiCTR2000039212,Recruiting,0,0,0
University of Hong Kong/Jiangsu Provincial CDC/Beijing Wantai Biological Pharmacy/Xiamen University,DelNS1-nCoV-RBD ,Phase I,BWBP DelNS1-nCoV-RBD,Vector (replicating),115,18–55,2,Yes,"Double-blind, dose-ranging",Hong Kong,29/03/2021,30/09/2022,NCT04809389,https://clinicaltrials.gov/ct2/show/NCT04809389,Recruiting,0,0,0
Gamaleya Research Institute,Gam-COVID-Vac/Sputnik V,Phase II,Gamaleya Gam-COVID-Vac/Sputnik V,Vector (non-replicating),110,≥60,2,No,Open-label,Russia,22/10/2020,30/03/2021,NCT04587219,https://clinicaltrials.gov/ct2/show/NCT04587219,"Active, not recruiting",0,0,0
Gamaleya Research Institute,Gam-COVID-Vac/Sputnik V,Phase I/II,Gamaleya Gam-COVID-Vac/Sputnik V,Vector (non-replicating),110,≥18,1,No,Open-label,Russia,15/01/2021,20/07/2021,NCT04713488,https://clinicaltrials.gov/ct2/show/NCT04713488,"Active, not recruiting",0,0,0
CanSino Biological Inc/Beijing Institute of Biotechnology,Ad5-nCoV,Phase I,Cansino Ad5-nCoV,Vector (non-replicating),108,18–60,1,No,"Open-label, dose-ranging",China,16/03/2020,30/12/2020,NCT04313127,https://clinicaltrials.gov/ct2/show/NCT04313127,"Active, not recruiting",0,0,0
"VIDO-InterVac,/University of Saskatchewan",COVAC,Phase I/II,VIDO COVAC,Protein subunit,108,≥18,2,Yes,"Observer-blind, dose-ranging",Canada,10/02/2021,31/10/2022,NCT04702178,https://clinicaltrials.gov/ct2/show/NCT04702178,Recruiting,0,0,0
Arcturus/Duke-NUS,LUNAR-COV19/ARCT-021,Phase II,Arcturus ARCT-021,RNA,106,≥18,1,No,Open-label,Singapore,04/01/2021,30/06/2022,NCT04728347,https://clinicaltrials.gov/ct2/show/NCT04728347,Recruiting,0,0,0
Gamaleya Research Institute,Gam-COVID-Vac/Sputnik V,Phase III,Gamaleya Gam-COVID-Vac/Sputnik V,Vector (non-replicating),100,18–60,2,Yes,Double-blind,Belarus,28/09/2020,28/03/2021,NCT04564716,https://clinicaltrials.gov/ct2/show/NCT04564716,"Active, not recruiting",0,0,0
Shenzhen Geno-Immune Medical Institute/(modified APC),aAPC vaccine,Phase I,SGMI aAPC,Other/Unknown,100,0.5–80,3,No,Open-label,China,15/02/2020,31/07/2023,NCT04299724,https://clinicaltrials.gov/ct2/show/NCT04299724,Recruiting,0,0,1
Shenzhen Geno-Immune Medical Institute/(modified DC),LV-SMENP-DC vaccine,Phase I/II,SGMI LV-SMENP-DC,Other/Unknown,100,0.5–80,1,No,Open-label,China,24/03/2020,31/07/2023,NCT04276896,https://clinicaltrials.gov/ct2/show/NCT04276896,Recruiting,0,0,1
University of Oxford/AstraZeneca/Gamaleya Research Institute,ChAdOx1-S,Phase III,Oxford ChAdOx1-S,Vector (non-replicating),100,≥18,2,No,Open-label,Russia,02/09/2020,11/05/2021,NCT04540393,https://clinicaltrials.gov/ct2/show/NCT04540393,Suspended,0,0,0
University of Oxford/AstraZeneca/Gamaleya Research Institute,ChAdOx1-S/Gam-COVID-Vac,Phase I/II,ChAdOx1-S/Gam-COVID-Vac prime-boost,Vector (non-replicating),100,≥18,2,Yes,Single-blind,"Belarus, Russia",30/03/2021,12/10/2021,NCT04684446,https://clinicaltrials.gov/ct2/show/NCT04684446,Not yet recruiting,1,0,0
University of Oxford/AstraZeneca/Gamaleya Research Institute,ChAdOx1-S/Gam-COVID-Vac,Phase II,ChAdOx1-S/Gam-COVID-Vac prime-boost,Vector (non-replicating),100,≥18,2,No,Open-label,Azerbaijan,10/02/2021,09/04/2021,NCT04686773,https://clinicaltrials.gov/ct2/show/NCT04686773,Not yet recruiting,1,0,0
University of Oxford/AstraZeneca/Gamaleya Research Institute,ChAdOx1-S/Gam-COVID-Vac,Phase I/II,ChAdOx1-S/Gam-COVID-Vac prime-boost,Vector (non-replicating),100,≥18,2,Yes,Single-blind,Pending,17/03/2021,01/05/2021,NCT04760730,https://clinicaltrials.gov/ct2/show/NCT04760730,Not yet recruiting,1,0,0
Vector Institute (peptide),EpiVacCorona,Phase I/II,Vector Institute EpiVacCorona,Protein subunit,100,18–60,2,Yes,"Open-label (phase I), double-blind (phase II)",Russia,27/07/2020,31/05/2021,NCT04527575,https://clinicaltrials.gov/ct2/show/NCT04527575,"Active, not recruiting",0,0,0
BioNTech/Pfizer/Fosun Pharma,BNT162 (b3),Phase I/II,BioNTech BNT162 (b3),RNA,96,18–85,2,No,"Open-label, dose-ranging",Germany,09/09/2020,31/03/2021,NCT04537949,https://clinicaltrials.gov/ct2/show/NCT04537949,"Active, not recruiting",0,0,0
Chula Vaccine Research Center/University of Pennsylvania,ChulaCov19,Phase I/II,Chulalongkorn ChulaCov19,RNA,96,18–75,2,No,"Open-label, dose-ranging",Thailand,01/01/2021,31/03/2021,NCT04566276,https://clinicaltrials.gov/ct2/show/NCT04566276,Not yet recruiting,0,0,0
Arcturus/Duke-NUS,LUNAR-COV19/ARCT-021,Phase I/II,Arcturus ARCT-021,RNA,92,21–80,1,Yes,Double-blind,Singapore,04/08/2020,31/12/2020,NCT04480957,https://clinicaltrials.gov/ct2/show/NCT04480957,Recruiting,0,0,0
Institut Pasteur/Themis/University of Pittsburg/Merck,V591/TMV-083,Phase I,Themis V591/TMV-083,Vector (replicating),90,18–55,1 or 2,Yes,"Double-blind, dose-ranging","Belgium, France",10/08/2020,30/11/2020,NCT04497298,https://clinicaltrials.gov/ct2/show/NCT04497298,Recruiting,0,0,0
ReiThera/Leukocare/Univercells,GRAd-COV2,Phase I,ReiThera GRAd-COV2,Vector (non-replicating),90,18–85,1,No,"Open-label, dose-ranging",Italy,10/08/2020,31/07/2021,NCT04528641,https://clinicaltrials.gov/ct2/show/NCT04528641,"Active, not recruiting",0,0,0
CanSino Biological Inc/Beijing Institute of Biotechnology,Ad5-nCoV,Phase I,Cansino Ad5-nCoV,Vector (non-replicating),89,18–60,1,No,Open-label,China,26/09/2020,25/10/2020,NCT04568811,https://clinicaltrials.gov/ct2/show/NCT04568811,"Active, not recruiting",0,0,0
Center for Genetic Engineering/and Biotechnology (peptide #2),CIGB-669,Phase I/II,CIGB CIGB-669,Protein subunit,88,19–54,3,Yes,Open-label,Cuba,07/12/2020,31/05/2021,RPCEC00000345,https://rpcec.sld.cu/en/trials/RPCEC00000345-En,Pending,0,0,0
BioNTech/Pfizer/Fosun Pharma,BNT162 (b2),Phase IV,BioNTech BNT162 (b2),RNA,80,≥18 (kidney transplant),2,No,Open-label,Belgium,17/02/2021,,2021-000412-28,https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000412-28/BE,Ongoing,0,0,0
Entos Pharmaceuticals,Covigenix VAX-001,Phase I/II,Entos Covigenix VAX-001,DNA,72,18–84,2,Yes,"Observer-blind, dose-ranging",Canada,01/03/2021,31/08/2021,NCT04591184,https://clinicaltrials.gov/ct2/show/NCT04591184,Not yet recruiting,0,0,0
Walter Reed Army Institute of Research,SpFN,Phase I,WRAIR SpFN,Protein subunit,72,18–55,2 or 3,Yes,"Double-blind, dose-ranging",Pending,05/04/2021,30/10/2022,NCT04784767,https://clinicaltrials.gov/ct2/show/NCT04784767,Not yet recruiting,0,0,0
Adimmune Corporation,AdimrSC-2f,Phase I,Adimmune AdimrSC-2f,Protein subunit,70,20–60,2,Yes,"Open-label, dose-ranging",Taiwan,24/08/2020,20/11/2020,NCT04522089,https://clinicaltrials.gov/ct2/show/NCT04522089,Recruiting,0,0,0
ImmunityBio Inc/NantKwest Inc,hAd5-S-Fusion+N-ETSD,Phase I,ImmunityBio hAd5-S-Fusion+N-ETSD,Vector (non-replicating),65,18–55,2 or 3,No,Open-label,USA,24/02/2021,30/04/2022,NCT04732468,https://clinicaltrials.gov/ct2/show/NCT04732468,Recruiting,0,0,0
Covaxx/United Biomedical Inc,UB-612,Phase I,Covaxx UB-612,Protein subunit,60,20–55,2,No,"Open-label, dose-ranging",Taiwan,25/09/2020,18/01/2021,NCT04545749,https://clinicaltrials.gov/ct2/show/NCT04545749,Recruiting,0,0,0
ImmunityBio Inc/NantKwest Inc,hAd5-S-Fusion+N-ETSD,Phase I,ImmunityBio hAd5-S-Fusion+N-ETSD,Vector (non-replicating),60,18–55,2,No,"Open-label, dose-ranging",USA,19/10/2020,19/11/2021,NCT04591717,https://clinicaltrials.gov/ct2/show/NCT04591717,Recruiting,0,0,0
Instituto Finlay de Vacunas (peptide #1),FINLAY-FR-1/Soberana 01A,Phase I,Instituto Finlay de Vacunas FINLAY-FR-1/Soberana 01A,Protein subunit,60,19–59,2 or 3,Yes,"Double-blind, dose-ranging",Cuba,19/10/2020,31/01/2021,IFV/COR/05,https://rpcec.sld.cu/en/trials/RPCEC00000338-En,Complete,0,0,0
Providence Therapeutics,PTX-COVID19-B,Phase I,Providence Therapeutics PTX-COVID19-B,RNA,60,18–64,2,Yes,"Observer-blind, dose-ranging",Canada,14/01/2021,30/04/2021,NCT04765436,https://clinicaltrials.gov/ct2/show/NCT04765436,Recruiting,0,0,0
University of Hong Kong/Jiangsu Provincial CDC/Beijing Wantai Biological Pharmacy/Xiamen University,DelNS1-nCoV-RBD,Phase I,BWBP DelNS1-nCoV-RBD,Vector (replicating),60,≥18,Unclear,Yes,Double-blind,China,01/09/2020,31/10/2021,ChiCTR2000037782,http://www.chictr.org.cn/historyversionpuben.aspx?regno=ChiCTR2000037782,Pending,0,0,0
Shifa Pharmed,Inactivated vaccine,Phase I,Shifa Pharmed vaccine,Inactivated,56,18–50,2,Yes,"Double-blind, dose-ranging",Iran,21/12/2020,18/02/2021,IRCT20201202049567N1,https://en.irct.ir/trial/52701,Complete,0,0,0
Anhui Zhifei Longcom Biopharmaceutical/Chinese Academy of Sciences,ZF2001,Phase I,AZLB ZF2001,Protein subunit,50,18–59,2,Yes,Double-blind,China,22/06/2020,21/07/2021,NCT04445194,https://clinicaltrials.gov/ct2/show/NCT04445194,Recruiting,0,0,0
Anhui Zhifei Longcom Biopharmaceutical/Chinese Academy of Sciences,ZF2001,Phase I,AZLB ZF2001,Protein subunit,50,≥60,Unclear,Yes,"Double-blind, dose-ranging",China,19/08/2020,18/12/2020,NCT04550351,https://clinicaltrials.gov/ct2/show/NCT04550351,"Active, not recruiting",0,0,0
SK Biosciences,NBP2001,Phase I,SK Biosciences NBP2001,Protein subunit,50,19–55,2,Yes,"Observer-blind, dose-ranging",Republic of Korea,17/12/2020,30/04/2021,NCT04760743,https://clinicaltrials.gov/ct2/show/NCT04760743,"Active, not recruiting",0,0,0
Codagenix/Serum Institute of India,COVI-VAC,Phase I,Codagenix COVI-VAC,Live-attenuated,48,18–30,1 or 2,Yes,"Double-blind, dose-ranging",UK,11/12/2020,30/06/2021,NCT04619628,https://clinicaltrials.gov/ct2/show/NCT04619628,Recruiting,0,0,0
Medigen Vaccine Biologics Corporation/NAID/Dynavax,MVC-COV1901,Phase I,Medigen MVC-COV1901,Protein subunit,45,20–50,2,No,"Open-label, dose-ranging",Taiwan,07/10/2020,30/06/2021,NCT04487210,https://clinicaltrials.gov/ct2/show/NCT04487210,"Active, not recruiting",0,0,0
Erciyes University (inactivated),ERUCOV-VAC,Phase I,Erciyes ERUCOV-VAC,Inactivated,44,18–55,2,Yes,"Double-blind, dose-ranging",Turkey,05/11/2020,01/03/2021,NCT04691947,https://clinicaltrials.gov/ct2/show/NCT04691947,Recruiting,0,0,0
GSK,CoV-2 SAM LNP,Phase I,GSK CoV-2 SAM LNP,RNA,40,18–50,2,No,"Open-label, dose-ranging",USA,15/02/2021,11/06/2021,NCT04758962,https://clinicaltrials.gov/ct2/show/NCT04758962,Recruiting,0,0,0
Instituto Finlay de Vacunas (peptide #2),FINLAY-FR-2/Soberana 02,Phase I,Instituto Finlay de Vacunas FINLAY-FR-2/Soberana 02,Protein subunit,40,19–59,2,No,"Open-label, dose-ranging",Cuba,02/11/2020,06/01/2021,IFV/COR/06,https://rpcec.sld.cu/en/trials/RPCEC00000340-En,Complete,0,0,0
Vaxine Pty/Medytox,COVAX-19,Phase I,Vaxine protein subunit vaccine,Protein subunit,40,18–65,2,Yes,Double-blind,Australia,30/06/2020,01/07/2021,NCT04453852,https://clinicaltrials.gov/ct2/show/NCT04453852,Recruiting,0,0,0
Gamaleya Research Institute,Gam-COVID-Vac/Sputnik V,Phase I/II,Gamaleya Gam-COVID-Vac/Sputnik V,Vector (non-replicating),38,18–60,1 or 2,No,Open-label,Russia,17/06/2020,03/08/2020,NCT04436471,https://clinicaltrials.gov/ct2/show/NCT04436471,Completed,0,0,0
Gamaleya Research Institute,Gam-COVID-Vac/Sputnik V,Phase I/II,Gamaleya Gam-COVID-Vac/Sputnik V (Lyo),Vector (non-replicating),38,18–60,1 or 2,No,Open-label,Russia,17/06/2020,03/08/2020,NCT04437875,https://clinicaltrials.gov/ct2/show/NCT04437875,Completed,0,0,0
OncoSec Medical Inc/Providence Cancer Institute,CORVax12,Phase I,OncoSec CORVax12,DNA,36,≥18,2,No,Open-label,USA,30/12/2020,31/05/2021,NCT04627675,https://clinicaltrials.gov/ct2/show/NCT04627675,"Active, not recruiting",0,0,0
Scientific and Technological Research Council,VLP vaccine,Phase I,STRC VLP vaccine,Virus-like particle,36,18–59,2,Yes,"Double-blind, dose-ranging",Turkey,27/03/2021,31/01/2022,NCT04818281,https://clinicaltrials.gov/ct2/show/NCT04818281,Recruiting,0,0,0
University Hospital Tübingen,CoVac-1,Phase I,Tübingen CoVac-1,Protein subunit,36,≥18,1,No,Open-label,Germany,27/11/2020,30/09/2021,NCT04546841,https://clinicaltrials.gov/ct2/show/NCT04546841,Recruiting,0,0,0
ImmunityBio Inc/NantKwest Inc,hAd5-S-Fusion+N-ETSD,Phase I,ImmunityBio hAd5-S-Fusion+N-ETSD,Vector (non-replicating),35,18–50,2,No,"Open-label, dose-ranging",South Africa,02/03/2021,30/04/2022,NCT04710303,https://clinicaltrials.gov/ct2/show/NCT04710303,Recruiting,0,0,0
Vaxart,VXA-CoV2-1,Phase I,Vaxart VXA-CoV2-1,Vector (non-replicating),35,18–54,2,No,"Open-label, dose-ranging",USA,21/09/2020,10/12/2020,NCT04563702,https://clinicaltrials.gov/ct2/show/NCT04563702,"Active, not recruiting",0,0,0
Shifa Pharmed,Inactivated vaccine,Phase I,Shifa Pharmed vaccine,Inactivated,32,51–75,2,Yes,Double-blind,Iran,13/03/2021,,IRCT20201202049567N2,https://en.irct.ir/trial/54885,Recruiting,0,0,0
Instituto Finlay de Vacunas (peptide #1),FINLAY-FR-1A/Soberana 01B,Phase I,Instituto Finlay de Vacunas FINLAY-FR-1A/Soberana 01B,Protein subunit,30,19–59,1,No,Open-label,Cuba,09/01/2021,13/02/2021,IFV/COR/07,https://rpcec.sld.cu/en/trials/RPCEC00000349-En,Complete,0,0,0
Ludwig Maximilian University of Munich,MVA-SARS-2-S,Phase I,Munich MVA-SARS-2-S,Vector (non-replicating),30,18–55,2,No,"Open-label, dose-ranging",Germany,05/10/2020,31/05/2021,NCT04569383,https://clinicaltrials.gov/ct2/show/NCT04569383,Recruiting,0,0,0
Osaka University/AnGes/Takara Bio,AG0301-COVID19,Phase I/II,AnGes AG0301-COVID19,DNA,30,20–65,2,No,"Open-label, dose-ranging",Japan,29/06/2020,26/09/2020,NCT04463472,https://clinicaltrials.gov/ct2/show/NCT04463472,"Active, not recruiting",0,0,0
Osaka University/AnGes/Takara Bio,AG0302-COVID19,Phase I/II,AnGes AG0302-COVID19,DNA,30,20–65,2 or 3,Yes,Open-label,Japan,31/08/2020,09/11/2020,NCT04527081,https://clinicaltrials.gov/ct2/show/NCT04527081,"Active, not recruiting",0,0,0
University of Oxford/AstraZeneca,ChAdOx1-S (intranasal),Phase I,Oxford ChAdOx1-S,Vector (non-replicating),30,19–40,1 or 2,Yes,"Open-label, dose-ranging",UK,01/03/2021,31/10/2021,NCT04816019,https://clinicaltrials.gov/ct2/show/NCT04816019,Not yet recruiting,0,0,0
Aivita Biomedical Inc,AV-COVID-19,Phase I,Aivita AV-COVID-19,Other/Unknown,27,≥18,1,Yes,"Double-blind, dose-ranging",Indonesia,07/12/2020,31/01/2021,NCT04685603,https://clinicaltrials.gov/ct2/show/NCT04685603,Recruiting,0,0,0
Aivita Biomedical Inc,AV-COVID-19,Phase I,Aivita AV-COVID-19,Other/Unknown,27,≥18,1,Yes,"Open-label, dose-ranging",Indonesia,07/12/2020,13/01/2021,NCT04690387,https://clinicaltrials.gov/ct2/show/NCT04690387,Completed,0,0,0
Symvivo,bacTRL-Spike,Phase I,Symvivo bacTRL-Spike,DNA,24,≥18,1,Yes,"Observer-blind, dose-ranging",Australia,02/11/2020,08/02/2022,NCT04334980,https://clinicaltrials.gov/ct2/show/NCT04334980,"Active, not recruiting",0,0,0
University of Queensland/CSL/Seqirus,aCoV2,Phase II/III,University of Queensland vaccine,Protein subunit,0,≥18,2,Yes,Observer-blind,Not applicable,15/12/2020,15/12/2020,NCT04806529,https://clinicaltrials.gov/ct2/show/NCT04806529,Withdrawn,0,0,0